PharmaTher has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) covering use of the painkiller ketamine for the treatment of Parkinson’s disease and motor disorders that cause uncontrolled, involuntary movements. A Notice of Allowance means the USPTO has decided to issue the…
News
EVER Pharma has launched a mobile app for the D-mine Pump, its portable micro-infusion pump designed to continuously deliver apomorphine under the skin (subcutaneously) to patients with Parkinson’s disease. The app was designed to train healthcare professionals and caregivers on how to use the pump and program the infusion device. It’s…
More co-existing health conditions in people with Parkinson’s disease is associated with a greater self-perception of stigma and a lower quality of life, a study has found. Thyroid disease, depression and anxiety each were linked to stigma and life quality, with demographic factors — including a younger age, less education…
Exposure to high concentrations of copper accelerates the formation of toxic clumps of the alpha-synuclein protein — a hallmark of Parkinson’s disease, a study shows. The study, “Single-Particle Resolution of Copper-Associated Annular α‑Synuclein Oligomers Reveals Potential Therapeutic Targets of Neurodegeneration,” was published in the journal…
Deep brain stimulation (DBS) may not put people with advanced Parkinson’s disease at a greater risk of excessive drooling, a common non-motor symptom also known as sialorrhea, according to a yearslong study of patients by researchers in Italy. Male sex, difficulty swallowing (dysphagia), and more severe disease, however, were…
Vitamin C may help to stabilize levodopa and carbidopa levels in the bloodstream of Parkinson’s disease patients who take laxatives containing magnesium oxide (MgO), which is thought to break down this common Parkinson’s treatment, a study suggested. Larger studies are needed to validate the benefits of vitamin C…
Placing sensors on the lower leg to measure acceleration and orientation with movement was the best way to detect freezing of gait symptoms in people with Parkinson’s disease, a small study suggested. These findings could be helpful for screening and treating freezing gait at early stages, the researchers noted.
Annovis Bio has been given the go-ahead by the U.S. Food and Drug Administration (FDA) to begin a Phase 3 clinical trial to test buntanetap (ANVS401) as an oral therapy for early-stage Parkinson’s disease. “With this FDA notice in hand, we are thrilled to…
Researchers have identified distinct changes to introns — a historically understudied component of genes — associated with the presence and progression of Parkinson’s disease. Learning more about these changes and the signaling pathways they impact may help in identifying biomarkers and treatment targets for the neurodegenerative disease, the researchers…
Although common, delirium often goes undocumented in the medical records of many Parkinson’s patients who experience the symptoms, results from a new study show, and those who have been diagnosed with delirium often lack instructions for future care. The study, “Documentation and Diagnosis of Delirium in Parkinson’s…
Recent Posts
- How being a skilled queen bee prepared me for Parkinson’s caregiving
- Grants fund tests of portable devices in Parkinson’s speech therapy
- Light therapy device seen to brighten life quality for those with Parkinson’s
- When early memories of Parkinson’s came full circle
- FDA grants advanced therapy status to Parkinson’s cell treatment